Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study finds.

Add Yahoo as a preferred source to see more of our stories on Google. The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly ...

The Food and Drug Administration has given Sandoz the green light for Tyruko (natalizumab-sztn), the first biosimilar to Biogen's Tysabri (natalizumab) injection for the treatment of adults with ...

Tysabri (natalizumab) helps treat forms of multiple sclerosis and Crohn’s disease. The drug comes as an infusion solution. Tysabri is not safe to receive in pregnancy and may not be safe to receive ...

The US Food and Drug Administration (FDA) has approved natalizumab-sztn injection (Tyruko, Sandoz), the first biosimilar to Biogen's Tysabri (natalizumab), to treat adults with relapsing forms of ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with ...

The FDA has approved the first biosimilar to treat multiple sclerosis, Sandoz's injection treatment natalizumab-sztn (Tyruko). Sandoz's injection treatment natalizumab-sztn (Tyruko) has been approved ...